计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Alicapistat (ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD) Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC 50 value of 395 nM .
In Vitro
Alicapistat exihibits inadequate CNS-penetration concentrations to obtain a pharmacodynamic effect. Calpain 1 (µ-calpain) and 2 (m-calpain) expression in a calcium-dependent manner with µ-molar or m-molar calcium concentrations required for their respective activation, respectively.\nAlicapistat (compound 22) (100 nM) prevents Aβ oligomer-induced deficits in synaptic transmission in rat. Alicapistat (compound 22) (385 nM) displays efficacy with respect to prevention of NMDA-induced neurodegeneration and A-induced synaptic dysfunction in rat hippocampal slice cultures. Alicapistat (9-21 nM) has the CSF concentrations without reaching the IC 50 for calpain inhibition and shows no dose-limiting toxicities (DLTs) in the broad populations studies. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Alicapistat (compound 22) (iv or po; 1-3 mg/kg) shows moderate mean plasma clearance values (CLp) in mouse, rat, and dog (0.13-1.04 L/hr.kg), while high in monkey (1.98 L/hr.kg). Mean steady-state volume of distribution values (Vss) were moderate in mouse, dog, and monkey (0.64-1.8 L/kg), but higher in rat (3.4 L/kg). The plasma elimination half-life (t 1/2 ) was shortest in dog (1.7 hours), followed by 2.3 hours in monkey and approximately 6.0 hours in mouse and rat. Oral bioavailability (F) values were high in mouse, rat, and dog (>80%), while moderate in monkey (14%). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:IC50: 395 nM (Human calpains 1)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机酸及其衍生物 |
| 类(Class) | 羧酸及其衍生物 |
| 亚类(Subclass) | 氨基酸、肽和类似物 |
| 中间层级节点(Intermediate Tree Nodes) | 氨基酸及其衍生物 - α氨基酸及其衍生物 |
| 直接上位类(Direct Parent) | 脯氨酸及其衍生物 |
| 其他上位类(Alternative Parents) | α-氨基酸酰胺 安非他明及其衍生物 吡咯烷酰胺 吡咯烷-2-酮 N-烷基吡咯烷 N-酰胺 叔羧酸酰胺 仲羧酸酰胺 内酰胺类 酮类 氮杂环化合物 有机光子化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 2-吡咯烷酮 - α-氨基酸酰胺 - 苯丙胺或衍生物 - 芳香族杂单环化合物 - 氮杂环 - 苯基化合物 - 羰基 - 羧酰胺基 - 脂肪酰基 - 脂肪酰胺 - 烃衍生物 - 酮 - 肟 - 单环苯基基团 - N-酰胺基胺 - N-烷基吡咯烷 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 脯氨酸或其衍生物 - 吡咯烷 - 吡咯烷羧酸或其衍生物 - 吡咯烷-2-甲酰胺 - 吡咯烷酮 - 醛基 - 叔羧酸酰胺 |
| 描述(Description) | 该化合物属于丙氨酸及其衍生物类有机化合物。这类化合物含有丙氨酸或其衍生物,这些衍生物可通过丙氨酸在氨基或羧基位置发生反应,或通过将甘氨酸的任意氢原子替换为杂原子而获得。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|